Argenx To Advance ARGX-119 To Registrational Trial For Congenital Myasthenic Syndromes

(RTTNews) - argenx SE (ARGX) announced that it plans to advance ARGX-119—a first-in-class agonist antibody targeting muscle-specific kinase (MuSK)—to a registrational study in patients with congenital myasthenic syndromes, following topline data from its Phase 1b trial.

Congenital Myasthenic Syndromes (CMS) are an ultra-rare and heterogenous group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of the neuromuscular junction.

The company noted that ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of its innovation model where its deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what's possible.

For More Such Health News, visit rttnews.com.